![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Arbor Biotechnologies
Main focus: Gene therapies and gene editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases (gene editing): Primary Hyperoxaluria, undisclosed liver diseases
Genome editing tool: CRISPR-Cas13d, multiple novel CRISPR variants
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://arbor.bio/
Pipeline: https://arbor.bio/our-approach
Gene editing partnerships: Vertex Pharmaceuticals, Vor Biopharma
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_arbor-logo_e9f94b6d00_17e9d94576.png)
Arbor Biotechnologies is a CRISPR-focused company that develops novel Cas variants for enhanced precision and efficacy. The company's lead programme is being developed for primary hyperoxaluria. The company is co-founded by CRISPR pioneer Feng Zhang and has established multiple collaborations, including but not limited to Vertex Pharmaceuticals and Vor Biopharma.